The present invention generally provides for a novel NEC-targeted strategy for the development of antiherpesviral drugs as well as for a novel antiviral strategy targeting the viral-cellular nuclear egress complex (NEC) for a small molecule-based therapy or prophylaxis to control infections with human cytomegalovirus or other pathogenic viruses of the group of the Herpesviridae. Methods for screening agents / compounds /small molecules modulating/ inhibiting the nuclear egress complex of Herpesviridae are provided as well. Specifically novel drug targets of the viral nuclear egress complex of viruses of the Herpesviridae are provided.